文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌局灶消融与调强放疗的毒性比较

The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-09-23

基于SEER-Medicare数据库,纳入2010-2017年诊断为前列腺癌的老年患者,将接受调强放疗(IMRT)者按2:1马氏匹配至局灶消融治疗(FT)者。结果显示FT组胃肠道毒性较低,但泌尿生殖毒性(尤其尿失禁和勃起功能障碍)风险高于IMRT组。

要点

  • FT组12个月内胃肠道毒性6.2%,低于IMRT组的9.5%(OR 0.63)。
  • FT组12个月内泌尿生殖毒性34.6%,高于IMRT组的15.8%(OR 2.69)。
  • FT组尿失禁治疗(17.4% vs 7.5%)和勃起功能障碍(18.2% vs 13.1%)均高于IMRT组。

核心结论

  • 在老年前列腺癌患者中,FT与较高的尿失禁和勃起功能障碍风险相关,而IMRT与较多的结肠炎和直肠出血相关。

研究设计与样本

  • 利用SEER-Medicare数据库识别2010-2017年诊断的前列腺癌患者,IMRT组按2:1马氏匹配至FT组,匹配因素包括人口学、合并症、疫苗接诊等。

主要发现

  • 匹配后FT组12个月内胃肠道毒性为6.2%,IMRT组为9.5%(OR 0.63,95%CI 0.45-0.88)。
  • 24个月胃肠道毒性FT组11.0%,IMRT组21.5%(OR 0.45,95%CI 0.35-0.58)。
  • 0-12个月泌尿生殖毒性FT组34.6%,IMRT组15.8%(OR 2.69,95%CI 2.21-3.28)。
  • 0-24个月泌尿生殖毒性FT组41.7%,IMRT组29.3%(OR 1.69,95%CI 1.42-2.01)。
  • 尿失禁治疗率FT组17.4% vs IMRT组7.5%(P<.01),勃起功能障碍FT组18.2% vs IMRT组13.1%(P<.01)。

临床怎么用

  • 对于老年前列腺癌患者,选择FT需权衡较高的尿失禁和勃起功能障碍风险,而IMRT需注意胃肠道毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Focal ablative therapy (FT) aims to treat prostate cancer (PCa) with reduced toxicity compared with standard radiation therapy. There is an absence of studies comparing FT and intensity modulated radiation therapy (IMRT) for PCa. METHODS AND MATERIALS: Using the SEER-Medicare database, we identified fee-for-service Medicare beneficiaries with PCa diagnosed from 2010 to 2017. Patients who underwent IMRT were Mahalanobis matched 2:1 to FT patients based on demographics, Medicaid eligibility, comorbidity, flu vaccination, primary care access, year, cancer characteristics, and androgen-deprivation therapy. We used logistic regression models to assess the relation between treatment modality and the presence of claims indicative of a gastrointestinal or genitourinary complication within 6, 12, and 24 months of treatment. RESULTS: We identified 9928 IMRT and 800 FT patients. After matching, patients treated with FT were less likely to have gastrointestinal toxicity (6.2%) within 12 months compared with IMRT patients (9.5%, odds ratio [OR]; 0.63 [95% CI, 0.45-0.88]); results were similar at 24 months (11.0% FT vs 21.5% for IMRT; OR, 0.45 [95% CI, 0.35-0.58]). Most gastrointestinal toxicity was because of diagnoses of rectal bleeding and colitis. In contrast, there were more claims indicative of genitourinary toxicity for FT compared with IMRT during the 0 to 12 (34.6% vs 15.8%; OR, 2.69 [95% CI, 2.21-3.28]) and 0 to 24 (41.7% vs 29.3%; OR, 1.69 [95% CI, 1.42-2.01]) month periods. The largest difference was in incontinence therapy (17.4% vs 7.5%, P < .01) and erectile dysfunction (18.2% vs 13.1%, P < .01), favoring IMRT. CONCLUSIONS: Among older patients with PCa, FT was associated with a higher risk of incontinence and impotence, than IMRT. There was more colitis and rectal bleeding with IMRT versus FT, but related procedures were rare and not significantly different.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yu JB, DeStephano DM, Jeffers B, et al. The Comparative Toxicity of Focal Ablation Versus Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 40998272. doi:10.1016/j.ijrobp.2025.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。